Disclosures for "A Survival Analysis of Beta-blocker Administration for Cardiovascular Disease in Patients With Glioblastoma"
-
Mr. Hanlon has nothing to disclose.
-
Mr. Rilinger has nothing to disclose.
-
Dr. Malkin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Worldwide Clinical Trials. Dr. Malkin has received publishing royalties from a publication relating to health care.
-
Author has nothing to disclose
-
Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anheart. Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeOnc. Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orbus. Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. The institution of Dr. Peereboom has received research support from Nuvation. The institution of Dr. Peereboom has received research support from Anheart. The institution of Dr. Peereboom has received research support from Pfizer. The institution of Dr. Peereboom has received research support from NeOnc. The institution of Dr. Peereboom has received research support from Bristol-Myers Squibb. The institution of Dr. Peereboom has received research support from Genentech/Roche. The institution of Dr. Peereboom has received research support from Orbus. The institution of Dr. Peereboom has received research support from GCAR.